These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 10852092)

  • 1. The role of carnitine supplementation during valproic acid therapy.
    Raskind JY; El-Chaar GM
    Ann Pharmacother; 2000 May; 34(5):630-8. PubMed ID: 10852092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carnitine in the treatment of valproic acid-induced toxicity.
    Lheureux PE; Hantson P
    Clin Toxicol (Phila); 2009 Feb; 47(2):101-11. PubMed ID: 19280426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-carnitine supplementation in childhood epilepsy: current perspectives.
    De Vivo DC; Bohan TP; Coulter DL; Dreifuss FE; Greenwood RS; Nordli DR; Shields WD; Stafstrom CE; Tein I
    Epilepsia; 1998 Nov; 39(11):1216-25. PubMed ID: 9821988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The decreased level of plasma carnitine in patients with epilepsy].
    Belousova ED
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6):106-110. PubMed ID: 28745680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carnitine deficiency and hyperammonemia associated with valproic acid therapy.
    Ohtani Y; Endo F; Matsuda I
    J Pediatr; 1982 Nov; 101(5):782-5. PubMed ID: 6813444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for a potential protective effect of carnitine-pantothenic acid co-treatment on valproic acid-induced hepatotoxicity.
    Felker D; Lynn A; Wang S; Johnson DE
    Expert Rev Clin Pharmacol; 2014 Mar; 7(2):211-8. PubMed ID: 24450420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of the effect of long term valproic acid treatment on plasma levels of carnitine, ammonia and amino acids related to the urea cycle in pediatric epileptic patients].
    Navarro-Quesada FJ; Lluch-Fernández MD; Vaquero-Abellán M; Marchante-Serrano C; Jiménez C
    Rev Neurol; 1997 Jul; 25(143):1037-44. PubMed ID: 9280630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carnitine deficiency during valproic acid treatment.
    Van Wouwe JP
    Int J Vitam Nutr Res; 1995; 65(3):211-4. PubMed ID: 8830002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs.
    Verrotti A; Greco R; Morgese G; Chiarelli F
    Int J Clin Lab Res; 1999; 29(1):36-40. PubMed ID: 10356662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum carnitine during valproic acid therapy.
    Laub MC; Paetzke-Brunner I; Jaeger G
    Epilepsia; 1986; 27(5):559-62. PubMed ID: 3093213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L-carnitine for acute valproic acid overdose: a systematic review of published cases.
    Perrott J; Murphy NG; Zed PJ
    Ann Pharmacother; 2010; 44(7-8):1287-93. PubMed ID: 20587742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of carnitine and fatty acid oxidation and its defects in infantile epilepsy.
    Tein I
    J Child Neurol; 2002 Dec; 17 Suppl 3():3S57-82; discussion 3S82-3. PubMed ID: 12597056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ammonia and carnitine concentrations in children treated with sodium valproate compared with other anticonvulsant drugs.
    Thom H; Carter PE; Cole GF; Stevenson KL
    Dev Med Child Neurol; 1991 Sep; 33(9):795-802. PubMed ID: 1936631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L-Carnitine supplementation to reverse hyperammonemia in a patient undergoing chronic valproic acid treatment: A case report.
    Maldonado C; Guevara N; Silveira A; Fagiolino P; Vázquez M
    J Int Med Res; 2017 Jun; 45(3):1268-1272. PubMed ID: 28425821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status.
    Hamed SA; Abdella MM
    Epilepsy Res; 2009 Sep; 86(1):32-41. PubMed ID: 19446440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of carnitine supplementation in valproate-induced hyperammonaemia.
    Böhles H; Sewell AC; Wenzel D
    Acta Paediatr; 1996 Apr; 85(4):446-9. PubMed ID: 8740302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?
    Lheureux PE; Penaloza A; Zahir S; Gris M
    Crit Care; 2005 Oct; 9(5):431-40. PubMed ID: 16277730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valproic Acid and the Liver Injury in Patients with Epilepsy: An Update.
    Guo HL; Jing X; Sun JY; Hu YH; Xu ZJ; Ni MM; Chen F; Lu XP; Qiu JC; Wang T
    Curr Pharm Des; 2019; 25(3):343-351. PubMed ID: 30931853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carnitine, valproate, and toxicity.
    Coulter DL
    J Child Neurol; 1991 Jan; 6(1):7-14. PubMed ID: 2002205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative systems pharmacology Model to characterize valproic acid-induced hyperammonemia and the effect of L-carnitine supplementation.
    Schiavo A; Maldonado C; Vázquez M; Fagiolino P; Trocóniz IF; Ibarra M
    Eur J Pharm Sci; 2023 Apr; 183():106399. PubMed ID: 36740101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.